ESMO 2023 | Multimodal artificial intelligence models in prostate cancer

Charles Parker, MBBS, UCL Cancer Institute, London, UK, discusses the development of digital pathology-based multimodal artificial intelligence (MMAI)-derived models for high-risk localized/metastatic prostate cancer. With the expansion of treatment options in this space, patients need further guidance on choosing the optimal treatment. Novel AI models can be integrated with various clinical variable to provide prognostic information, which has been attempted in the STAMPEDE trial (NCT00268476). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.